Clinical trials
Advanced Malignant Tumors clinical trials
Below are recruiting advanced malignant tumors clinical trials, each written for real people, not researchers. We’re tracking 1,034 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Birmingham, AlabamaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT07189195RecruitingPhase 1
TR-002 for advanced solid tumors and pancreatic cancer
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT05631964RecruitingPhase 1
Early trial of BL-M07D1 for advanced HER2-positive digestive tumors
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07098299RecruitingPhase 1
Metformin with chemotherapy or immunotherapy for advanced solid tumors
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
Bay City, MichiganAges 18 years+ - NCT07483554RecruitingPhase 2
IBI343 combination therapy for advanced solid tumors
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT05518253RecruitingPhase 1
CAR-T treatment for CD70-positive advanced solid tumors
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hangzhou, ZhejiangAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05918445RecruitingPhase 1/Phase 2
PM8002 for advanced solid tumors that have stopped responding
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
BaojiAges 18–75 - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06051760RecruitingPhase 1
NV-001 for advanced solid tumors after standard treatments
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06769152RecruitingPhase 2
HLX43 for advanced gynecological cancers
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Ji'nan, ShandongAges 18–75 - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT07121036RecruitingPhase 1
High-dose vitamin C infusion for advanced solid tumors
This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.
Wuhan, HubeiAges 18–75 - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT05067283RecruitingPhase 1
Study of Calderasib for KRAS G12C advanced cancers
This trial tests a new drug, Calderasib, for people with advanced solid tumors that have a specific mutation called KRAS G12C. It may help if your cancer has not responded to previous treatments or if you have certain types of lung or colorectal cancer.
Tampa, FloridaAges 18 years+ - NCT06820424RecruitingEarly Phase 1
CDH17-targeted CAR-T cells for advanced solid tumors
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Kunming, YunnanAges 18–75 - NCT07321574RecruitingPhase 2
Testing ABP1011T for advanced solid tumors
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
Luoyang, HenanAges 18–75 - NCT06015048RecruitingPhase 1/Phase 2
SHR-A1811 plus other therapies for advanced HER2+ tumors
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
Hefei, AnhuiAges 18–75
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant tumors?
- Yes. Clin2 currently lists 1,034 recruiting advanced malignant tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.